ReviewCureus2025
The Use and Role of Mesalamine in the Treatment of Ulcerative Colitis: A Literature Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Water-triggered in-situ gelling phospholipid oil enema for enhanced budesonide delivery and mucosal healing in ulcerative colitis.International journal of pharmaceutics: X · 2026Article
- Stem cell-based tactics in the remodeling and treatment of intestinal diseases.Stem cell research & therapy · 2026Review
- Advancing ulcerative colitis therapy: a review of 5-ASA synergy with traditional Chinese medicine and natural bioactive compounds.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the most common forms of Inflammatory bowel disease amongst adolescents, with chronic relapsing and inflammation involving the colonic mucosa, is ulcerative colitis (UC). Though various possible causative theories have been linked to the development of this condition, the standard treatment approach for mild to moderate cases of UC has been mesalamine. Its use in UC has been primarily due to its anti-inflammatory properties, such as the inhibition of inflammatory cytokines, and a less common side effect profile. The main objective of this study has been to highlight underutilized clinical strategies and support evidence-informed decisions regarding the use of mesalamine for both achieving and sustaining remission in patients with UC across varying age groups. Hence, through this paper, the key results and findings, such as the modest risk of repercussions associated with mesalamine, its suitability for prolonged use, and its chemoprotective feature, will provide more confidence among both physicians and patients in using mesalamine for UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.